Pro Medicus Limited (ASX: PME) is experiencing a significant stock rally, fueled by recent contract wins in the U.S. and a confident outlook on artificial intelligence (AI) from management.
The medical imaging software company has seen its shares rise over 6% following major contract announcements, including a seven-year, A$16 million deal with TidalHealth and a five-year renewal worth A$28 million with Allegheny Health Network. These developments are part of a broader trend, with Pro Medicus reporting over A$400 million in total contract value for FY26, marking one of its strongest sales years yet.
In a recent interview, CEO Dr. Sam Hupert addressed concerns about AI disrupting established healthcare software firms. He argued that the company’s recent successes contradict the notion that AI will replace traditional imaging platforms, instead suggesting that AI could enhance Pro Medicus' competitive edge. He views the integration of AI in diagnostic imaging as a growth opportunity rather than a threat, highlighting the company's readiness to support AI-driven workflows in major healthcare systems.
Pro Medicus is also expanding its offerings beyond radiology into cardiology, which aligns with the industry's trend toward unified imaging platforms. The company anticipates a significant increase in transaction volumes as new contracts are implemented, positioning itself as a key player in the evolving landscape of healthcare AI. The market's positive response indicates that many investors view Pro Medicus as well-prepared for the next phase of AI integration in healthcare, countering broader sector concerns.